GnRH agonist decreases endothelial nitric oxide synthase (eNOS) expression in leiomyoma

International Journal of Gynecology and Obstetrics

Volumn 70, Issue 3, 2000, Pages 347-352

  Gokdeniz, R ^a   Ozen, S ^a   Mizrak, B ^a   Bazoglu, N ^a  

^a INONU UNIVERSITY   (Turkey)

Author keywords

GnRHa; Immunohistochemistry; Leiomyoma; Nitric oxide

Indexed keywords

GONADORELIN AGONIST; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; TRIPTORELIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; MYOMETRIUM; PRIORITY JOURNAL; UTERUS MYOMA; UTERUS TUMOR;

EID: 0034283905     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7292(00)00198-3     Document Type: Article

References (25)

1. Friedman A.J. Treatment of uterine myomas with GnRH agonists. Semin Reprod Endocrinol. 11:1993;154-161.
2. Filicori M., Hall D.A., Loughlin J.S., Rivier J., Vale W., Crowley W.F. A conservative approach to the management of uterine leiomyoma: pituitary desensitization by a luteinising hormone-releasing hormone analogue. Am J Obstet Gynecol. 147:1983;726-727.
3. Andreyko J.L., Blumenfeld Z., Marshall L.A., Monroe S.E., Hricak H., Jaffe R.B. Use of an agonistic analog of gonadotrophin-releasing hormone nafarelin to treat leiomyomas: assessment by magnetic resonance imaging. Am J Obstet Gynecol. 158:1988;903-910.
4. Shaw R.W. Mechanism of LHRH analogue action in uterine fibroids. Horm Res. 32:1989;150-153.
5. Aleem F.A., Predanic M. The hemodynamic effect of GnRH agonist therapy on uterine leiomyoma vascularsity: a prospective study using transvaginal color Doppler sonography. Gynecol Endocrinol. 9:1995;253-258.
6. Lumsden M.A., West C.P., Bramley T., Rumgay L., Baird T. The binding of epidermal growth factor to human uterus and leiomyomata in women rendered hypestrogenic by continuous administration of an LHRH agonist. Br J Obstet Gynecol. 95:1988;1299-1304.
7. Rein M.S., Friedman A.J., Pandian M.R., Heffner L.J. The secretion of insulin-like growth factors I and II by the explant culture of fibroids and myometrium from women treated with gonadotrophin-releasing hormone agonist. Obstet Gynecol. 76:1990;388-394.
8. Matta W.H.M., Stabile I., Shaw R.W., Campell S. Doppler assessment of uterine blood flow changes in patients with fibroids receiving gonadotrophin-releasing hormone agonist buseralin. Fertil Steril. 46:1988;1083-1085.
9. Gokdeniz R, Mizrak B, Ozen S, Bazoglu N. eNOS expression in leiomyoma and parental myometrium. Gynecol Obstet Invest (in press).
10. Remmele W., Stegner H.E. Immunohistochemischer Nachweis von Östrogenrezeptoren ER-ICA im Mammakarzinomgewebe. Der Frauenarzt. 2:1987;41-43.
11. Cirkel U., Ochs H., Roehl A., Scneider H.P.G. Estrogen and progesterone receptor content of enucleated uterine myomata after luteinising hormone-releasing hormone. Acta Obstet Gynecol Scand. 73:1994;328-332.
12. Chegini N., Rong H., Dou Q., Kipersztok S., Williams S. Gonadotropin-releasing hormone GnRH and GnRH receptor gene expression in human myometrium and leiomyomata and the direct action of GnRH analogs on myometrial smooth muscle cells and interaction with ovarian steroids in vitro. J Clin Endocrinol Metab. 81:1996;3215-3321.
13. Mizutani T, Sugihara A, Nakamuro K, Terada N. Suppression of cell proliferation and induction of apoptosis in uterine leiomyoma by gonadotrophin-releasing hormone agonist Leuprolide acetate. J Clin Endocrinol Metab. 83:1998;1253-1255.
14. Colgan T.J., Pendergast S., LeBklanc M. The histopathology of uterine leiomyomas following treatment with gonadotrophin-releasing hormone analogues. Hum Pathol. 24:1993;1073-1077.
15. Sreenan J.J., Prayson R.A., Biscotti C.V., Thornton M.H., Easley K.A., Hart W.R. Histopathologic findings in 107 uterine leiomyomas treated with leuprolide acetate compared with 126 controls. Am J Surg Pathol. 20:1996;427-432.
16. Huang S.C., Chou C.Y., Lin Y.S., Tsai Y.C., Hsu K.F., Liu C.H., Huang K.E. Enhanced deoxyribonucleic acid damage and repair but unenhanced apoptosis in uterine leiomyomas treated with gonadotrophin-releasing hormone agonist. Am J Obstet Gynecol. 177:1997;417-424.
17. Rein M.S., Barbieri R.L., Friedman A.J. Progesterone: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol. 172:1995;14-18.
18. Veille J.C., Li P., Eisenach J.C., Massmann A.G., Figueroa J.P. Effects of estrogen on nitric oxide biosynthesis and vasorelaxant activity in sheep uterine and renal arteries. Am J Obstet Gynecol. 174:1996;1043-1049.
19. Bryant C.E., Tomlinson A., Mitchell J.A., Thiermerman C., Willoughby D.A. Nitric oxide synthase in the rat fallopian tube is regulated during estrous cycle. J Endocrinol. 146:1995;149-157.
20. Figueroa J.P., Massaman A.G. Estrogen increases nitric oxide synthase activity in the uterus of nonpregnant sheep. Am J Obstet Gynecol. 173:1995;1539-1545.
21. Khartinov S.A., Logan-Sinclair R.B., Busset C.M., Shinebourne E.A. Peak expiratory nitric oxide differences in men and women: relation to the menstrual cycle. Br Heart J. 72:1994;243-245.
22. Gilligan D.M., Badar D.A., Panza J.A., Quyyumi A.A., Cannon R.O. The effects of estrogen on endothelium-dependent vasodilation in postmenopausal women. Circulation. 88:1993;79.
23. Hoyle C.H., Stones R.W., Robson T., Whitley K., Burnstock G. Innervation of vasculature and microvasculature of the human vagina by NOS and neuropeptide-containing nerves. J Anat. 188(3):1996;633-644.
24. Berman R.J., McCarthy M.M., Kyprianou N. Effect of estrogen withdrawal on nitric oxide synthase expression and apoptosis in the rat vagina. Urology. 51(4):1998;650-656.
25. Rutgers J.L., Spong C.Y., Sinow R., Heiner J. Leuprolide acetate treatment and myoma arterial size. Obstet Gynecol. 86:1995;386-388.